Blood Gas Analyzer Market Size, Share and Business Intelligence

The global market for blood gas analyzers is expected to reach USD 636.0 Million by 2021, at a CAGR of 4.6% during the forecast period of 2016 to 2021.

(EMAILWIRE.COM, January 17, 2019 ) According to the new market research "Blood Gas Analyzer Market by Product/Brand (GEM 4000, GEM 3000, i-STAT, ABL900, ABL90, cobas b 221, RAPIDLab), Player/Company (Radiometer, Instrumentation Laboratory, Siemens, Abbott, Alere) - Global Forecasts to 2021", The global market for blood gas analyzers is expected to reach USD 636.0 Million by 2021, at a CAGR of 4.6% during the forecast period of 2016 to 2021.

The growth in blood gas analyzer market is majorly attributed to the rising demand for automated and point-of-care blood gas analyzer devices. These analyzers offer rapid analysis and are easy to use, portable, and offer short turnaround times, which make them valuable tools for managing oxygenation and ventilation of patients in ICUs and emergency departments.
Furthermore, the integration of blood gas analyzers with electronic medical records and laboratory information systems are providing lucrative potential for expansion of this market. These integrated systems not only enable effective monitoring of patients’ health, but also streamline the workflow. Also, the growing demand for technology-integrated combined systems and miniaturization of POC blood gas analyzer are expected to provide growth opportunities in the coming years.
However, availability of refurbished devices, non-FDA approved analyzers and unfavorable reimbursement scenario across the globe are restricting the growth of this market. Additionally, unavailability of software for data analysis is the prime factor hindering growth of this blood gas analyzers market on a whole.
Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=242278963
The blood gas analyzer market is segmented on the basis of major product brands (i-STAT, epoc, GEM 3000, GEM 3500, GEM 4000, ABL800, ABL80, ABL90, cobas b 221, cobas b 121, cobas b 123, RAPID Series) in four major regional segments, namely, North America, Europe, APAC, and Rest of the World. This report analyzes the market from both value and volume perspectives. GEM 3000 is expected to account for the largest share of the global blood gas analyzers market in 2016. This is mainly because GEM 3000 delivers real-time system diagnostics, requires low labor-intensive system calibration, and eliminates lengthy equipment training and possible human errors. On the other hand, epoc (Alere) is expected to be the fastest-growing brand in the coming years.

North America is expected to account for the largest market share in 2016, which is primarily attributed to the growing prevalence of lifestyle diseases, increasing number of product approvals, and rising government initiatives in this region.
Leading players in blood gas analyzer market are focusing on the launch of new and improved products as their key growth strategy. The major players in the global blood gas analyzers market are Abbott Laboratories (U.S.), Alere, Inc. (U.S.), Instrumentation Laboratory (U.S.), Radiometer (Denmark), Roche Diagnostics (Switzerland), and Siemens Healthcare (Germany). Radiometer is expected to command the largest share in this market with the launch of its flagship products ABL800 and ABL90.

North America is estimated to dominate the global blood gas analyzer market in 2016. The large share of this regional segment can primarily be attributed to the growing prevalence of lifestyle diseases, increasing number of product approvals, and rising government initiatives. On the other hand, the Asia-Pacific market is expected to witness the highest growth during the forecast period, owing to factors such as growing initiatives by market players and increasing patient population base in this region.

Players in this market adopted organic (new product launch) as well as inorganic growth strategies (acquisitions and agreements) to enhance their market shares and positions. New product launch was the most dominant strategy adopted by market players between 2013 and 2016.


Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com